Peter Mundel

Dr. Mundel joined Goldfinch Bio after serving as a consultant to Third Rock Ventures, where he played an important role in the creation and launch of Goldfinch Bio. He brings to the company more than 25 years of experience as a leader in academic research, most recently at Massachusetts General Hospital and Harvard Medical School. A major focus of Dr. Mundel’s work has been the development of precision therapeutics for patients with kidney diseases through a mechanistic understanding of the cell biology and pathophysiology of the kidney, with a focus on podocytes.

A pioneer of molecularly targeted treatment for proteinuric kidney disease, Dr. Mundel has published more than 150 peer-reviewed manuscripts, including in high impact journals such as the New England Journal of Medicine, Nature Medicine, and Nature Cell Biology, and has given numerous invited lectures nationally and internationally. He was inducted into the American Society for Clinical Investigation in 2003, and has received numerous awards including a Top10 award from the Clinical Research Forum and the Young Investigator Award from the American Society of Nephrology. Dr. Mundel holds an M.D. from the University of Heidelberg, Germany“